The Pharma Data

SEPTEMBER 9, 2020

billion doses by the end of 2021. During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. billion doses by the end of 2021. and Germany as well as animal immunogenicity studies. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JULY 21, 2021

Pfizer and BioNTech expect that Biovac’s Cape Town facility will be incorporated into the vaccine supply chain by the end of 2021. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. Pfizer Disclosure Notice.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 7, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The information contained in this release is as of May 7, 2021. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

MAY 6, 2021

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. The information contained in this release is as of May 6, 2021. This press release features multimedia. View the full release here: [link]. Pfizer Disclosure Notice.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

OCTOBER 4, 2023

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs. 52 , 79–91 (2020).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98

Disease Immune Response Therapies Treatment 98

Agency IQ

JUNE 9, 2023

However, this guideline is primarily intended to provide recommendations on evaluating the immune system’s response to small molecule drugs. The guidance contains recommendations for small molecule drugs, as well as any biological products that fall within CDER’s purview.

FDA 40

FDA Science Small Molecule Immune Response 40

Drug Discovery World

FEBRUARY 2, 2023

The pharmaceutical equivalent of “dilettante”— predictably with no less of a negative connotation—is the term “polypharmacologic”, which refers to agents that act, usually unintentionally or serendipitously, on a plethora of molecular targets or biochemical pathways. 2021 Jun;18(6):1425-1436. Cell Mol Immunol.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Progress on implementation of the Corporate Social Responsibility strategy. Change at CER.

Vaccine 52

Vaccine Production FDA FDA Approval 52

The Pharma Data

DECEMBER 10, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in the U.S.,

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

Drug Discovery World

APRIL 12, 2023

Testing new modality drugs poses additional challenges The drug development pipeline is no longer predominantly composed of small molecule drugs. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Drug Discovery World

JANUARY 20, 2023

Testing new modality drugs poses additional challenges The drug development pipeline is no longer predominantly composed of small molecule drugs. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

The Pharma Data

OCTOBER 14, 2020

. Results from the PRECISION Study Expected in First Half of 2021. 15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. President and Chief Executive Officer of Tonix Pharmaceuticals. About Tonix Pharmaceuticals Holding Corp. CHATHAM, N.J., 1 Noyce RS, et al. 2018) PLoS One.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

FEBRUARY 22, 2021

Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. Rigel’s lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials and will begin Phase 2 clinical trials in 2021 as part of the collaboration. Rigel Pharmaceuticals, Inc., vice president of immunology at Lilly. About Rigel.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Immune Response 40

The Pharma Data

JUNE 26, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. These results were published in Nature in July 2020. About BioNTech.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Pharma Data

DECEMBER 20, 2020

Pfizer and BioNTech announced additional data on neutralizing antibody and T-cell responses from their Phase I/II trial of their COVID-19 vaccine conducted in Germany. It hopes to include more than 4,000 people in additional trials, with a possible regulatory approval by the fourth quarter of 2021.

Vaccine 52

Vaccine Trials Small Molecule Therapies 52

The Pharma Data

SEPTEMBER 9, 2020

producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFN? billion doses by the end of 2021.

Vaccine 52

Vaccine RNA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 15, 2020

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. The FDA has set an action date of July 7, 2021. Oral, Small Molecules. Avacopan is an orally-administered selective complement 5a receptor inhibitor.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

SEPTEMBER 15, 2020

Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises. The Company currently plans to perform an interim analysis with 20 patients and 12 months of ABR in 2021. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

MARCH 11, 2021

Findings from the analysis were derived from de-identified aggregate Israel MoH surveillance data collected between January 17 and March 6, 2021, when the Pfizer-BioNTech COVID-19 Vaccine was the only vaccine available in the country and when the more transmissible B.1.1.7 The information contained in this release is as of March 11, 2021.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

JUNE 24, 2021

government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022. Deliveries of the 200 million doses will begin in August 2021 and continue through the remainder of the year. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. BioNTech COVID-19 Vaccine.

Government 52

Government Vaccine Clinical Trials Licensing 52